Please ensure Javascript is enabled for purposes of website accessibility

Another Hard Pill to Swallow

By Brian Lawler – Updated Nov 15, 2016 at 4:33PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

A former FDA chief will take the fall for not disclosing holdings, but the pharmaceuticals industry needs more than that.

There was the scandal involving clinical trials and institutional investors last year, the Martha Stewart-ImClone insider trading case, and sketchy stock sales by a congressman. Now comes news that Lester Crawford, the former head of the Food and Drug Administration, will plead guilty to failing to disclose financial holdings in companies affected by the agency while he was in charge.

Crawford's reign as the top FDA official was very brief. He was interim FDA chief for about a year; after President Bush finally nominated him, and he was approved to lead the agency in July 2005, he suddenly resigned in September. Initially, nobody knew why because Crawford gave no reason, but I think we can now make a pretty good conjecture about it.

The Justice Department is accusing Crawford of falsely reporting sales of stock in companies affected by FDA rulings, yet still holding the shares. That would have represented a huge conflict of interest, and lying about selling the shares would have only made things worse.

The punishment for these alleged improprieties isn't particularly harsh. According to his lawyer, Crawford is going to plead guilty to two misdemeanors and will "admit his financial disclosures had errors and omissions."

While there are no explicit insider trading allegations against Crawford and his actions aren't nearly on the level of other past indiscretions in the industry, these things make investors think the deck is stacked against them when it comes to investing in biotech and pharmaceutical stocks.

It's hoped the new FDA commissioner, Andrew von Eschenbach, can keep a greater distance between his personal investments and the agency's regulatory dealings. The integrity of the agency and even the pharmaceutical and biotech sectors depends on it.

Need new ideas for your money? Talk stocks with other investors and our analysts when you give our newsletters a try.

Fool contributor Brian Lawler does not own shares of any company mentioned in this article. The Fool has a disclosure policy.

None

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
329%
 
S&P 500 Returns
106%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 09/24/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.